skip nav
National Prevention Information Network
Search Help
Other Searches: Search Organizations | Search Materials | Search Campaign Resources | Search Funding
Share Share this page on Twitter Share this page on Facebook Share this page on LinkedIn View more options to share this page E-mail this page to a colleague Print this page

<< Back


Evaluation of the Latent Reservoir in HIV-Infected Infants and Children with Early Antiretroviral Treatment and Virologic Control (R01)

Grant Amount: In fiscal year 2014, NICHD intends to commit $1,500,000 total costs to fund 3-6 awards; NIAID intends to commit $1,400,000 total costs to fund 3-6 awards.

This funding opportunity announcement (FOA) invites grant applications from institutions/organizations that propose to conduct studies of the latent reservoir in HIV-infected children who have had early treatment (antiretroviral therapy [ART] initiated at <6 months of age) and have had continuous viral suppression. These studies can be in developed or developing countries. Studies to create new or adapt existing animal models of perinatal HIV infection and early treatment can also be proposed.

Applicants should propose novel methods for evaluating the latent reservoir and factors associated with such reservoirs in children with perinatal HIV infection who had early treatment and continuous viral suppression. Studies to create new or adapt existing animal models of perinatal infection and early treatment can also be proposed. Appropriate comparison populations should be included as needed for both human and animal studies.

Areas of interest include, but are not limited to:

Evaluate whether early ART in children affects proviral reservoir size, immune activation, and level of persistent viremia;
Conduct studies to identify and quantify the tissues and cell types that constitute the persistent viral reservoir in children receiving early ART;
Evaluate the impact of early infection and treatment on the developing brain;
Develop tools to measure and quantify HIV in reservoirs such as novel imaging techniques or novel molecular and culture assays appropriate for use in pediatric populations;
Investigate the role of immune activation, inflammation, and their mediators in various tissues on HIV persistence in infants with perinatal HIV infection;
Evaluate whether duration of viral suppression after ART, the time from birth until viral suppression is achieved on ART, and/or the timing of infection (in utero, intrapartum, postpartum) is associated with viral reservoir size, ongoing viremia, immune activation, and HIV-specific immune responses in HIV-infected children;
Identify and validate viral and host cellular factors and functions involved in the persistence of HIV infection despite ART that could be targeted for eradication of persistent virus in HIV-infected children;
Delineate the viral, host, and immune mechanisms involved in the persistence of HIV infection despite effective ART, and the establishment and maintenance of the latent viral reservoir in HIV-infected children;
Host factors (including epigenetics) and viral genetic factors in the establishment and maintenance of HIV-1 persistence in the setting of suppressive ART in children.
Funding Organization
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Division of AIDS
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Fund Category
Support Types
Eligible Organizations
City Agencies
Commercial Organizations
Community Based Organizations
County Agencies
Educational Organizations/Institutions
Federal Government Agencies
International Agencies
IRS 501 (c)(3) Organizations
Nonprofit Organizations
Religious Organizations
State Agencies
Tribal Organizations
Award Amount Notes
The following NIH components intend to commit the following amounts in fiscal year 2014:

NICHD intends to commit $1,500,000 total costs to fund 3-6 awards.
NIAID intends to commit $1,400,000 total costs to fund 3-6 awards.
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Future year amounts will depend on annual appropriations.
Letter of Intent Date
Application Due Date
Project Start Date
Application Contact Customer Support
Phone: (800) 518-4726
Technical Contact
Rohan Hazra
Phone: (301) 435-6868
Fund Duration
Up to 5 years.
Antiretroviral Drugs
Children with HIV/AIDS
Medical Treatments and Therapies
Perinatal Transmission
Application Process
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at

It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide (, except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Web Site
Fund Number

Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN. Fund Record #4647

<< Back

Contact Us
About Us
HIV Content Notice
Privacy Policy
Policies & Disclaimers
Site Index
Help Using the CDC NPIN Web Site

CDC NPIN Searches

Search Organizations
Search Materials
Search Funding Opportunities
Search Campaign Resources
Help Using the CDC NPIN Searches

CDC NPIN Resources
STD Awareness Microsite
AIDS Gov Logo and Link CDC Logo and Link